Skip to main content
. 2011 Aug 1;4(4):249–257. doi: 10.1593/tlo.11136

Figure 4.

Figure 4

(A) Levels of apoptotic cells (as indicated by cleaved caspase 3 staining) were quantified in A549 tumor sections obtained from tumors excised at various time points after treatment with CVX-045 (30mg/kg 1x/wk). There was a significant (P < .01, ANOVA, Tukey multiple comparison posttest, n = 5 per group) increase in apoptosis of CVX-045-treated tumors compared with PBS-treated tumors at 2 and 4 weeks. (B) Microvessel density (as indicated by CD31 reactivity) was quantified in A549 tumor sections obtained from tumors excised at various time points after treatment with CVX-045 (30 mg/kg 1x/wk). There was a significant (P < .05, ANOVA, Tukey multiple comparison posttest, n = 5 per group) decrease in microvessel density observable between PBS-treated and CVX-045-treated tumors at 2 weeks. (C) The percentage of PCNA-positive cells was quantified in A549 tumors after 4 weeks of CVX-045 treatment (30 mg/kg 1x/wk). A significant (P < .05, Mann-Whitney test, n = 5 per group) decrease in PCNA staining was observed in the CVX-045-treated group at 4 weeks.